Posted by Michael Wonder on 06 Jul 2022
Agenda for July 2022 PBAC meeting (version 3)
6 July 2022 - It is actually version 4.
The Department of Health has published yet another version of the agenda for this month's PBAC meeting.
The submission for cemiplimab (Libtayo) has been withdrawn. On 1 July 2022, Regeneron Pharmaceuticals announced that it had completed the acquisition of Sanofi's stake in Libtayo (cemiplimab). Could the withdrawal of the submission be related to this transaction?
